Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-in-human imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate.
Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, Morris MJ, Lewis JS, Rudin CM, Poirier JT. Tendler S, et al. Among authors: bodei l. medRxiv [Preprint]. 2024 Jan 11:2024.01.10.24301109. doi: 10.1101/2024.01.10.24301109. medRxiv. 2024. PMID: 38260492 Free PMC article. Preprint.
Lesion Dosimetry for [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer.
Grkovski M, O'Donoghue JA, Imber BS, Andl G, Tu C, Lafontaine D, Schwartz J, Thor M, Zelefsky MJ, Humm JL, Bodei L. Grkovski M, et al. Among authors: bodei l. J Nucl Med. 2023 Nov;64(11):1779-1787. doi: 10.2967/jnumed.123.265763. Epub 2023 Aug 31. J Nucl Med. 2023. PMID: 37652541 Free PMC article.
Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs.
Bodei L, Michael Tuttle R, Grewal RK, Mauguen A, Augensen F, Abusamra M, Mahajan S, Jayaprakasam VS, Osborne JR, Haque S, Wong BZY, Ghossein RA, Fagin J, Schӧder H, Ho A, Humm JL, Larson SM. Bodei L, et al. Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):325-329. doi: 10.1007/s00259-023-06420-z. Eur J Nucl Med Mol Imaging. 2024. PMID: 37712994 Free PMC article. No abstract available.
Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force.
Koumarianou A, Filosso PL, Bodei L, Castano JP, Fernandez-Cuesta L, Deroose CM, Foll M, Dromain C, Reed NS, Caplin M, Capdevila J, Falkerby J, Faggiano A, Frilling A, Grande E, Hicks RJ, Kasajima A, Kos-Kudla B, Krishna BA, Lim E, Rinke A, Singh S, Thirlwell C, Volante M, Walter T. Koumarianou A, et al. Among authors: bodei l. J Neuroendocrinol. 2024 May 16:e13412. doi: 10.1111/jne.13412. Online ahead of print. J Neuroendocrinol. 2024. PMID: 38754956
Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
Rubino M, Di Stasio GD, Bodei L, Papi S, Rocca PA, Ferrari ME, Fodor CI, Bagnardi V, Frassoni S, Mei R, Fazio N, Ceci F, Grana CM. Rubino M, et al. Among authors: bodei l. Endocrine. 2024 May;84(2):704-710. doi: 10.1007/s12020-024-03707-5. Epub 2024 Feb 7. Endocrine. 2024. PMID: 38324106
213 results